FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping

OBJECTIVE: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. CLINICAL PRESENTATION AND INTERVENTION: A 46-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Yung-Sung, Huang, Meng-Lin, Chang, Se-Fen, Chen, Chin-Fan, Hu, Huang-Ming, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586907/
https://www.ncbi.nlm.nih.gov/pubmed/24642571
http://dx.doi.org/10.1159/000358799
_version_ 1783261903194161152
author Yeh, Yung-Sung
Huang, Meng-Lin
Chang, Se-Fen
Chen, Chin-Fan
Hu, Huang-Ming
Wang, Jaw-Yuan
author_facet Yeh, Yung-Sung
Huang, Meng-Lin
Chang, Se-Fen
Chen, Chin-Fan
Hu, Huang-Ming
Wang, Jaw-Yuan
author_sort Yeh, Yung-Sung
collection PubMed
description OBJECTIVE: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. CLINICAL PRESENTATION AND INTERVENTION: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. CONCLUSION: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity.
format Online
Article
Text
id pubmed-5586907
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-55869072017-11-01 FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping Yeh, Yung-Sung Huang, Meng-Lin Chang, Se-Fen Chen, Chin-Fan Hu, Huang-Ming Wang, Jaw-Yuan Med Princ Pract Case Report OBJECTIVE: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. CLINICAL PRESENTATION AND INTERVENTION: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. CONCLUSION: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity. S. Karger AG 2014-09 2014-03-08 /pmc/articles/PMC5586907/ /pubmed/24642571 http://dx.doi.org/10.1159/000358799 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
spellingShingle Case Report
Yeh, Yung-Sung
Huang, Meng-Lin
Chang, Se-Fen
Chen, Chin-Fan
Hu, Huang-Ming
Wang, Jaw-Yuan
FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
title FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
title_full FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
title_fullStr FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
title_full_unstemmed FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
title_short FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
title_sort folfiri combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after ugt1a1 genotyping
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586907/
https://www.ncbi.nlm.nih.gov/pubmed/24642571
http://dx.doi.org/10.1159/000358799
work_keys_str_mv AT yehyungsung folfiricombinedwithbevacizumabasfirstlinetreatmentformetastaticcolorectalcancerpatientswithhyperbilirubinemiaafterugt1a1genotyping
AT huangmenglin folfiricombinedwithbevacizumabasfirstlinetreatmentformetastaticcolorectalcancerpatientswithhyperbilirubinemiaafterugt1a1genotyping
AT changsefen folfiricombinedwithbevacizumabasfirstlinetreatmentformetastaticcolorectalcancerpatientswithhyperbilirubinemiaafterugt1a1genotyping
AT chenchinfan folfiricombinedwithbevacizumabasfirstlinetreatmentformetastaticcolorectalcancerpatientswithhyperbilirubinemiaafterugt1a1genotyping
AT huhuangming folfiricombinedwithbevacizumabasfirstlinetreatmentformetastaticcolorectalcancerpatientswithhyperbilirubinemiaafterugt1a1genotyping
AT wangjawyuan folfiricombinedwithbevacizumabasfirstlinetreatmentformetastaticcolorectalcancerpatientswithhyperbilirubinemiaafterugt1a1genotyping

Ejemplares similares